(1) Background: Ectopic fat deposition and its effects, metabolic syndrome, have been significantly correlated to lifestyle and caloric consumption. There is no specific noninvasive evaluation tool being used in order to establish clinical markers for tracing the metabolic pathway implicated in obesity-related abnormalities that occur in the body as a result of a high-fat diet (HFD). The purpose of this work is to investigate in vivo ectopic fat distribution and in vitro metabolite profiles given by HFDs, as well as how they are inter-related, in order to find surrogate metabolic biomarkers in the development of metabolic syndrome utilizing noninvasive approaches. (2) Methods: Male Wistar rats were divided into a standard normal chow diet, ND group, and HFD group. After 16 weeks of different diet administration, blood samples were collected for proton nuclear magnetic resonance (1H NMR) and biochemical analysis. Magnetic resonance imaging/proton magnetic resonance spectroscopy (MRI/1H MRS) was performed on the abdomen, liver, and psoas muscle of the rats. (3) Results: Visceral fat showed the strongest relationship with blood cholesterol. Although liver fat content (LFC) was not associated with any biophysical profiles, it had the highest correlation with metabolites such as (-CH2)n very-low-density lipoprotein/low-density lipoprotein (VLDL/LDL), lactate, and N-acetyl glycoprotein of serum 1H NMR. HFD showed no obvious influence on muscle fat accumulation. Acetoacetate, N-acetyl glycoprotein, lactate, (-CH2)n VLDL/LDL, and valine were the five possible metabolic biomarkers used to differentiate HFD from ND in the present study. (4) Conclusions: Our study has validated the influence of long-term HFD-induced ectopic fat on body metabolism as well as the metabolic profile deterioration both in vivo and in vitro.
Obesity is a risk factor for chronic kidney disease. The expansion of adipose tissues in obesity induces insulin resistance and low-grade systemic inflammation, promoting kidney damage. Our previous studies have demonstrated that agomelatine (AGOM) exerts renoprotective effects in experimental models of obesity and insulin resistance through various mechanisms, including the attenuation of ER stress and oxidative stress. This study aimed to further explore the effects of agomelatine on renal inflammation, insulin signaling, and necroptosis in obese, insulin-resistant rats. Obesity was induced in rats with a high-fat diet for 16 weeks, followed by 4 weeks of treatment with 20 mg kg−1 day−1 of AGOM or 10 mg kg−1 day−1 of pioglitazone (PIO). The results showed that insulin resistance was improved after treatment with AGOM and PIO, as demonstrated by the reduction in fasting plasma glucose, insulin, and HOMA-IR. Both treatments restored the levels of renal insulin signaling proteins. Moreover, AGOM inhibited TNFα, TNFR1, NF-ĸB, COX2, and IL1β, which attenuated the necroptosis-related proteins RIPK3 and MLKL. AGOM also prevented kidney DNA fragmentation, as detected by the TUNEL assay. In an obese condition, the level of the tight junction protein claudin-1 (CLDN1) was enhanced after being treated with AGOM. In conclusion, the novel mechanisms associated with AGOM and involved in limiting kidney injury were the inhibition of the TNFα/NF-ĸB/p-RIPK3 pathway and a reduction in inflammation and necroptosis. This suggested that AGOM could be an effective treatment for inhibiting kidney dysfunction in cases of obesity and insulin resistance. These findings open new avenues for the management of renal dysfunction, with implications for personalized medicine.
Diabetic nephropathy (DN) is a major complication of chronic hyperglycemia. Although fish gelatin hydrolysate has antioxidant, anti-inflammatory, and antihypertensive properties, its renoprotective effects in DN remain unclear. This study investigated its effects on renal oxidative stress, inflammation, fibrosis, and endoplasmic reticulum (ER) stress in diabetic rats. Thirty male Wistar rats were fed a normal chow diet or a high-fat diet for 4 weeks. Diabetes was induced in high-fat-diet-fed rats by a single intraperitoneal injection of streptozotocin (30 mg/kg). Diabetic rats were randomly assigned to receive no treatment (untreated diabetes), gelatin hydrolysate at 250 or 500 mg/day, or metformin at 100 mg/kg/day groups (n = 6/group), while normal-chow-fed rats served as controls. Treatments were orally administered for 8 weeks. High-dose gelatin hydrolysate improved metabolic disturbances and renal dysfunction, whereas low-dose gelatin hydrolysate and metformin more effectively reduced oxidative stress, as indicated by decreased 8-OHdG expression. All treatments reduced renal injury, fibrosis, and inflammatory markers. ER stress-related proteins were also attenuated, with the greatest changes observed in IRE1/XBP1-associated markers. These findings provide in vivo evidence that GLH treatment is associated with improved renal outcomes and reduced markers of oxidative stress, inflammation, fibrosis, and ER stress in DM rats.
(1) Background: Adipocyte differentiation involves coordinated changes in mitochondrial activity, redox balance, and cellular metabolism. Here, we examined how quercetin affects lipid accumulation and associated mitochondrial-redox and metabolic features during 3T3-L1 adipogenic differentiation by combining functional assays with time-resolved 1H NMR metabolomics. (2) Materials and methods: 3T3-L1 cells were differentiated for six days in the absence or presence of 20 μM quercetin. Lipid accumulation, mitochondrial membrane potential, intracellular reactive oxygen species (ROS), and intracellular metabolite profiles were assessed at defined stages of differentiation. (3) Results: Quercetin reduced lipid accumulation, mitochondrial membrane potential, and ROS accumulation, particularly at the mid-to-late stages of adipogenic differentiation. 1H NMR analysis showed lower lipid-associated resonances and changes in metabolites related to energy metabolism, choline metabolism, and amino acid metabolism in quercetin-treated cells. Orthogonal partial least squares-discriminant analysis (OPLS-DA) showed separation of the metabolic profiles of untreated and quercetin-treated cells at each measured stage. The variables contributing to this separation included lipid-associated resonances, lactate, 3-hydroxybutyrate, choline-related metabolites, and selected amino acids. (4) Conclusions: The results indicate that quercetin reduces lipid accumulation during adipogenic differentiation in association with changes in mitochondrial-redox status and intracellular metabolic profiles. Overall, the findings support stage-dependent alterations of metabolic profiles in quercetin-treated 3T3-L1 cells during adipogenic differentiation.